Bortezomib resistance and MUC1 in myeloma

Blood

Volumn 123, Issue 19, 2014, Pages 2910-2912

  Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BORTEZOMIB; GLUTATHIONE; GO 203; MUCIN 1; P53 INDUCIBLE REGULATOR OF GLYCOLYSIS AND APOPTOSIS PROTEIN; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; (ARGININE)9-CYSTEINYL-GLUTAMINYL-CYSTEINYL-ARGINYL-ARGINYL-LYSYL-ASPARAGINE; BORONIC ACID DERIVATIVE; C12ORF5 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; PEPTIDE; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE;

CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; MULTIPLE MYELOMA CELL LINE; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; HUMAN; METABOLISM;

BORONIC ACIDS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCIN-1; PEPTIDES; PYRAZINES; REACTIVE OXYGEN SPECIES;

EID: 84900386517     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563882     Document Type: Review

References (10)

1. Yin L, Kufe T, Avigan D, Kufe D. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death. Blood. 2014;123 (19):2997-3006.
2. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA. 1993;90 (1):282-286. (Pubitemid 23010294)
3. Stroopinsky D, Rosenblatt J, Ito K, et al. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013;73 (17):5569-5579.
4. Yin L, Ahmad R, Kosugi M, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010;78 (2):166-174.
5. Cloosen S, Gratama J, van Leeuwen EB, et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol. 2006;135 (4):513-516. (Pubitemid 44583416)
6. Ahmad R, Raina D, Joshi MD, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009; 69 (17):7013-7021.
7. Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012;287 (40): 33436-33446.
8. Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by downregulating TIGAR expression and depleting NADPH. Blood. 2012;119 (3):810-816.
9. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278 (36): 33714-33723. (Pubitemid 37553204)
10. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136 (5):823-837.